Loading...
Market
Will Roche increase its stake in Poseida beyond 66% by January 2026?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Roche's financial disclosures or press releases
Story
Roche Completes $1.5 Billion Acquisition of Poseida Therapeutics, Securing 66% Stake by January 8
Jan 8, 2025, 12:15 PM
Roche Holdings AG has successfully completed its tender offer for Poseida Therapeutics, Inc., acquiring a 66% stake in the U.S. genetic engineering firm. The transaction, valued at approximately $1.5 billion, aims to enhance Roche's capabilities in developing new cancer treatments. The acquisition is set to finalize on January 8, 2025, following the completion of the tender offer, which saw significant participation from shareholders.
View original story
Similar markets
Switch • 25%
No majority stakeholder • 25%
New investor • 25%
Current majority stakeholder • 25%
No • 50%
Yes • 50%
